Professor Isaiah Ibeh of the University of Benin in Nigeria this week announced the development of a new drug that can allegedly “cure” HIV and AIDS.
Ibeh, dean of the School of Basic Medical Sciences of the university, told reporters in Benin that the herbal drug had undergone “series of successful tests.”
“We are at the threshold of making history, in the sense that we seem to have with us something that will permanently take care of what over time seems to have defied all solutions,” he said.
“We are talking about the latest discovery of an oral drug made from plants extraction in Nigeria for the possible cure of the pandemic, HIV and AIDS virus.”
The evidence must be examined by medical researchers worldwide before the importance of these new developments can be determined, said Damon Francis, ,Medical Director, Health Care for Homeless, Alameda County Public Health Department, who also works at East Bay AIDS Clinic in Oakland.
“I look forward to hearing more, in particular the evidence,” he said.
According Ibeh, research on the project was started in 2010 and culminated in the development of “Deconcotion X (DX)-Liquid or Bioclean 11 for the cure of HIV and AIDS”.
“The existing retroviral drugs are intervention drugs for the management of AIDS but our new discovery is a possible cure,” he said. “We have tried to look at the product first; its toxicological analysis and discovered that it has a large safety margin.
“This means that if animals or human beings are exposed to it, they will not suffer any serious harm at all from the exposure.
“We have also done the bacteriological analysis on it, after which we looked at its effect on the virus and the result was quite revealing and refreshing.”
Ibeh also said that the drug had been exposed to series of medical examination both in Nigeria and in the USA. He added that the drug had performed well on patients with the HIV virus and had shown evidence of total restoration of damaged tissues.
“The result showed an increase in the body weight of the individual administered with DX.
“But preliminary results showed that of the five latest patients orally administered with the drugs, our findings are that up to seven months, three of them were siro negative while two were sill faintly positive.”
Ibeh appealed for support from the Nigerian government to assist the university with equipment to support the research.
Jesse Brooks contributed to this article.